Reproterol
![]() | |
Systematic (IUPAC) name | |
---|---|
(RS)-7-(3-{[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino}propyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Inhalation (MDI), IV |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
54063-54-6 ![]() |
ATC code | R03AC15 (WHO) |
PubChem | CID 25654 |
ChemSpider |
23898 ![]() |
UNII |
11941YC6RN ![]() |
KEGG |
D08474 ![]() |
ChEMBL |
CHEMBL1095607 ![]() |
Chemical data | |
Formula | C18H23N5O5 |
Molar mass | 389.406 g/mol |
| |
| |
![]() ![]() |
Reproterol (INN) is a short-acting[1] β2 adrenoreceptor agonist used in the treatment of asthma.[2]
References
- ↑ Küpper, T; Goebbels, K; Kennes, LN; Netzer, NC (December 2012). "Cromoglycate, reproterol, or both—what's best for exercise-induced asthma?". Sleep & breathing = Schlaf & Atmung 16 (4): 1229–35. PMID 22198635.
- ↑ Virchow JC Jr. Reproterol: beta-2-agonist, theophylline, or both? Respiration. 1999;66(3):210-1. PMID 10364735
|
This article is issued from Wikipedia - version of the Sunday, April 10, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.